Catalogue en ligne OFDT Documentation

AB-CHMINACA. Report on the risk assessment of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) in the framework of the Council Decision on new psychoactive substances

Titre :	AB-CHMINACA. Report on the risk assessment of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) in the framework of the Council Decision on new psychoactive substances
Auteurs :	OEDT = EMCDDA
Type de document :	Rapport
Editeur :	Lisbon : OEDT / EMCDDA, 2018
Autre Editeur :	Luxembourg : Publications Office of the European Union
Collection :	Risk assessments, ISSN 1725-4493, num. 24
Format :	67 p.
Langues:	Anglais
Discipline :	PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Mots-clés :	Organismes OEDT Thésaurus mots-clés CANNABINOIDES ; CONTROLE DES STUPEFIANTS ; FACTEUR DE RISQUE ; DROGUES DE SYNTHESE ; PHARMACOLOGIE ; TYPE D'USAGE ; EFFET SECONDAIRE ; TOXICITE ; INTOXICATION ; MORTALITE ; SURVEILLANCE EPIDEMIOLOGIQUE Thésaurus géographique EUROPE
Résumé :	This publication presents the data and findings of the risk assessment on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place AB-CHMINACA in Schedule II of the Convention on Psychotropic Substances of 1971 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.
Note de contenu :	TABLE OF CONTENTS: - Foreword. - EMCDDA actions on monitoring and responding to new drugs Europol-EMCDDA Joint Report on AB-CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) - a summary. - Risk Assessment Report on a new psychoactive substance: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA). - Technical report on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA). - Participants of the risk assessment meeting, 7-8 November 2017.
Domaine :	Drogues illicites / Illicit drugs
Lien :	http://www.emcdda.europa.eu/publications/risk-assessments/ab-chminaca_en